Lobe Sciences Ltd. reports news as a clinical-stage biopharmaceutical company that acquires preclinical and early-stage therapeutic assets and advances them through focused subsidiaries. Its development model centers on formulation work, intellectual property protection, regulatory engagement, and program-specific funding structures.
Recurring updates include progress for Cynaptec Pharmaceuticals' L-130 program and Applied Lipid Technologies' S-100 program, including disease areas such as chronic cluster headache and sickle cell disease. Company news also covers financial results, private placements, working-capital actions, investor relations engagements, healthcare conference participation, and public-company governance changes.
Lobe Sciences (OTCQB:LOBEF) announced a non-brokered private placement of 14,615,384 common shares at $0.065 per share for aggregate gross proceeds of approximately $950,000 on April 10–11, 2026.
The company said proceeds will fund working capital and general corporate expenses; the placement is subject to regulatory approvals, a four-month Canadian hold period, and securities are not registered for sale in the United States.
Lobe Sciences (OTCQB:LOBEF) reported a materially improved financial position as of March 25, 2026. Liabilities fell ~81% from $2.35M to $0.44M; cash rose from $0.24M to $5.99M; net working capital improved by $6.1M to $4.05M; outstanding warrants fell ~70% to ~13M. The company adopted a subsidiary-based, capital-efficient model and sold a 34% interest in Cynaptec to strengthen runway and reduce dilution risk.
Management converted most convertible notes into equity on favorable terms and noted the recent audit omitted a going-concern explanatory paragraph.
Lobe Sciences (OTCQB:LOBEF, CSE:LOBE) announced the promotion of Mr. Mirza Rahimani to Chief Financial Officer, effective March 2, 2026. Mr. Rahimani joined the company December 1, 2025 as a financial advisor and brings over 15 years of experience in accounting, financings, M&A and public-company reporting under IFRS and US GAAP.
He succeeds Mr. Yong Yao, who previously served as CFO through an arrangement with Century Biolabs. The change is presented as part of management alignment to support strategic transactions and regulatory compliance.
Lobe Sciences (OTCQB:LOBEF) announced that CEO Dr. Frederick D. Sancilio will be in Miami, Florida during the Jefferies and Leerink Healthcare Conferences on March 2026 and is available for investor and partner meetings.
The company advances preclinical and early-stage therapeutic assets via focused subsidiaries and is currently progressing two patented programs: L-130 for chronic cluster headache and S-100 for sickle cell disease, with additional programs under evaluation in substance use disorder and other neurological indications.
Lobe Sciences (OTCQB:LOBEF) reported Q1 fiscal 2026 results for the quarter ended November 30, 2025, highlighting increased R&D activity and maintained liquidity. Cash was $5.99M, short-term investments $1.03M, and net working capital $4.05M. R&D rose to $982,087 as L-130 preclinical and regulatory work advanced; net loss was $1.31M. The company reiterated progress via its 64% subsidiary Cynaptec (L-130) and early-stage S-100 program, while noting commercialization and reimbursement uncertainty for a medical food effort in Georgia.
Lobe Sciences (OTCQB:LOBEF) appointed Mr. Nick Karakochuk to its Board of Directors effective January 13, 2026, to bolster governance and capital markets expertise as the company builds on fiscal 2025 momentum.
Mr. Karakochuk is a corporate and securities lawyer focused on mergers and acquisitions, public and private financings, corporate reorganizations, and exchange and securities compliance. In connection with his appointment he was granted 3,500,000 restricted share units under the company's equity incentive plan.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and an operational update following a leadership transition. Key balance-sheet improvements include cash of $5,854,118, a working capital surplus of $5,163,526, and short-term investments of $1,686,688 as of August 31, 2025. The current portion of convertible notes was eliminated and derivative liability fell to $205,105. FY2025 net loss attributable to the parent was $4,861,611 (loss per share $0.03). The company moved its L-130 program into subsidiary Cynaptec and completed a subsidiary financing that raised $8.46 million at a $22.56 million post-money valuation while retaining 64% ownership. Management says the changes reduce liquidity risk and focus development on two core programs for FY2026.
Lobe Sciences (OTCQB:LOBEF) reported audited FY2025 results and outlined a strategic transformation after a late‑2024 leadership and board change. The company strengthened liquidity: cash $5,854,118, short‑term investments $1,686,688, and working capital $5,163,526 as of August 31, 2025. FY2025 net loss attributable to parent was $4,861,611 (loss per share $0.03). Management moved its lead program L‑130 into subsidiary Cynaptec, which completed a $8,460,000 financing at a $22,560,000 post‑money valuation, leaving Lobe with a 64% stake. Company emphasized reduced legacy liabilities, improved governance, and focus on L‑130 (cluster headache) and S‑100 (sickle cell disease) while noting commercialization and reimbursement risks for a proprietary medical food.
Lobe Sciences (OTCQB:LOBEF) closed a related‑party debt settlement on October 23, 2025, issuing 3,837,686 common shares at C$0.05 per share to settle USD 137,130 (CAD 191,884.32) owed to Clearway Global, LLC.
The settlement is intended to strengthen the balance sheet and preserve cash for growth. The Settlement Shares carry a statutory four‑month hold period under Canadian securities laws. The creditor is a related party (holds >20% and is owned/controlled by a director/officer) and the directors relied on exemptions under MI 61‑101 for valuation and minority approval.
Lobe Sciences (OTCQB:LOBEF) announced a proposed related‑party debt settlement on October 9, 2025 converting USD 137,130 (CAD 191,884.32) of accounts payable into 3,837,686 common shares at C$0.05 per share. The Settlement Shares will carry a statutory four‑month hold period and closing is subject to Canadian Securities Exchange approval. The creditor, Clearway Global, is a related party holding >20% and owned by a director/officer; the company relied on MI 61‑101 exemptions for valuation and minority approval. Management said the conversion strengthens the balance sheet and preserves cash for growth.